Mar 5 |
Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress
|
Mar 5 |
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
|
Feb 19 |
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership
|
Feb 9 |
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
|
Feb 9 |
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
|
Dec 18 |
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
|
Nov 25 |
Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdings
|